Who we are

Founded by Philippe Carteron de Balmont in 2004, CarthaGenetics® has focused on finding innovative early patients access to Orphan Drugs and is now a pioneer with one of the broadest experiences in the field of Rare Diseases.
CarthaGenetics® helps international biotech companies involved in Orphan Drugs and Advanced Therapies development to step not only in the complex European markets (including Turkey) but also in the fast-growing North African markets.
CarthaGenetics® is a team of close to twenty life sciences experts committed to delivering innovative therapies to patients.

CarthaGenetics® has direct presence in Switzerland, France, Germany, Spain, Italy, Turkey, Algeria, Tunisia and through an extended network of local experts in each country/area who are familiar with access to orphan drugs in their own market. We also cover with proven track records Portugal, Bulgaria, Malta, Belgium, The Netherlands, Luxembourg, Azerbaijan, and Morocco.

At CarthaGenetics®, we believe that product development must be driven by a solid understanding of the environment within which the candidate product will be launched, and the criteria by which elements of the development will be assessed by both regulators and payers. We start from science and medical needs, as we collaborate with our clients’ teams to drive innovative products along development, prelaunch and commercialization.
CarthaGenetics® will be your partner of choice to start operations in Europe and to expand in North African countries.

Our Commitment

CarthaGenetics® focuses on Orphan Drugs and Advanced Therapies areas with unmet needs. Good health is vital to all of us, and finding sustainable access to innovative treatments is our motto. That’s why we are committed to providing patients and physicians with innovative drugs in development.

To ensure we can continue to deliver on our commitment to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of people involved in healthcare decisions. Through working in partnership with everyone from patient groups to healthcare providers, healthcare authorities and non-governmental organizations, our goal is to ensure that people have access on time to innovative treatments.

We always act in an ethical manner, respecting patients’ rights and local
legislations.

Pioneer Market Access

In order to answer our customer needs about “Pricing and Reimbursement”, CarthaGenetics® has created in 2008 Pioneer Market Access, a separate entity dedicated to market access services offerings for biotech and pharmaceutical firms plus medical devices across Europe, orchestrating and managing projects from acquisition until execution. Developing and implementing strategic marketing and business analysis/planning tailored to specific clients’ needs and current market position, designing local market access strategies per product and country to maximise market reach and potential revenues.

Leading client-based projects focused on price analysis, market research, reimbursement negotiations and market entry sequence strategies. Driving price negotiation , lobbying as needed to ensure client interests are protected.

Preparing reimbursement dossiers for France, Switzerland, Germany,  the Netherlands Providing services in multilinguistic and multicultural environments, with clients based in Europe, United States, Canada, and Japan.

Please contact us at:  phc@pioneer-market-access.com

Eshmoun Biomedical

Eshmoun Biomedical is an entity of CarthaGenetics®, created in 2014 dedicated to the generic area for North African markets (Algeria, Morocco, Tunisia). Eshmoun (or Eshmun) was the Phoenician/ Punic god of healing and one of the tutelary god of Carthage.

Eshmoun Biomedical is specialized in registration processes and tenders participation for generics in Central Pharmacies of Tunisia, Algeria & Morocco.

Please contact us at:  eshmoun@carthagenetics.com